Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Preclinical studies identifying carboplatin as a viable cisplatin alternative.

Literature DB >> 3910219

Preclinical studies identifying carboplatin as a viable cisplatin alternative.

Abstract

The claims of eight cisplatin analogues as viable alternatives to the parent drug are discussed in terms of their toxicities, antitumour properties and potential biochemical selectivities. It is concluded that, of the eight, diammine (1,1-cyclobutane dicarboxylato)platinum(II) (carboplatin, CBDCA, JM8) had the features most desirable to merit its clinical evaluation.

Entities: Chemical Disease Gene

Mesh：

Substances：

Year: 1985 PMID： 3910219 DOI： 10.1016/0305-7372(85)90015-5

Source DB: PubMed Journal: Cancer Treat Rev ISSN： 0305-7372 Impact factor: 12.111

Keyword Cloud
Cited

48 in total

Review 1. Novel metals and metal complexes as platforms for cancer therapy.

Authors: Michael Frezza; Sarmad Hindo; Di Chen; Andrew Davenport; Sara Schmitt; Dajena Tomco; Q Ping Dou
Journal: Curr Pharm Des Date: 2010-06 Impact factor: 3.116

2. Dinuclear platinum(II) complexes of imidazophenanthroline-based bridging ligands as potential anticancer agents: synthesis, characterization, and in vitro cytotoxicity studies.

Authors: Carlson Alexander; N U Prajith; P V Priyanka; A Nithyakumar; N Arockia Samy
Journal: J Biol Inorg Chem Date: 2019-04-03 Impact factor: 3.358

3. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.

Authors: L R Kelland; M Jones; G Abel; M Valenti; J Gwynne; K R Harrap
Journal: Cancer Chemother Pharmacol Date: 1992 Impact factor: 3.333

4. In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin.

Authors: R C Gaver; A M George; G Deeb
Journal: Cancer Chemother Pharmacol Date: 1987 Impact factor: 3.333

5. Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study.

Authors: L T Vlasveld; J H Beynen; W Boogerd; W W Ten Bokkel Huinink; S Rodenhuis
Journal: Cancer Chemother Pharmacol Date: 1990 Impact factor: 3.333

10. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.

Authors: D K Kim; H T Kim; Y B Cho; J H Tai; J S Ahn; T S Kim; K H Kim; W S Hong
Journal: Cancer Chemother Pharmacol Date: 1995 Impact factor: 3.333

Preclinical studies identifying carboplatin as a viable cisplatin alternative.

Review 1. Novel metals and metal complexes as platforms for cancer therapy.

2. Dinuclear platinum(II) complexes of imidazophenanthroline-based bridging ligands as potential anticancer agents: synthesis, characterization, and in vitro cytotoxicity studies.

3. Human ovarian-carcinoma cell lines and companion xenografts: a disease-oriented approach to new platinum anticancer drug discovery.

4. In vitro stability, plasma protein binding and blood cell partitioning of 14C-carboplatin.

5. Complete remission of brain metastases of ovarian cancer following high-dose carboplatin: a case report and pharmacokinetic study.

Review 6. An integrated view of cisplatin-induced nephrotoxicity and ototoxicity.

Review 7. Trial watch - inhibiting PARP enzymes for anticancer therapy.

8. X-ray Structure of the Carboplatin-Loaded Apo-Ferritin Nanocage.

Review 9. Satraplatin: leading the new generation of oral platinum agents.

10. Antitumor activity of cis-malonato[(4R,5R)-4,5-bis(aminomethyl)-2- isopropyl-1,3-dioxolane]platinum(II), a new platinum analogue, as an anticancer agent.